- Markets
- Healthcare
- SHUKRAPHAR
SHUKRAPHAR
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Shukra Pharmaceuticals To Consider Issue Of Shares
Sept 23 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
TO CONSIDER ISSUE OF SHARES
Source text for Eikon: ID:nBSE80yvw6
Further company coverage: SHUR.BO
(([email protected];;))
Sept 23 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
TO CONSIDER ISSUE OF SHARES
Source text for Eikon: ID:nBSE80yvw6
Further company coverage: SHUR.BO
(([email protected];;))
Shukra Pharmaceuticals Names Anar Jayesh Patel As CFO
July 10 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
NAMES ANAR JAYESH PATEL AS CFO
Source text for Eikon: ID:nBSE3C1xXt
Further company coverage: SHUR.BO
(([email protected];))
July 10 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
NAMES ANAR JAYESH PATEL AS CFO
Source text for Eikon: ID:nBSE3C1xXt
Further company coverage: SHUR.BO
(([email protected];))
Shukra Pharmaceuticals To Consider Issuance Of Fully Paid Up Bonus Shares
Feb 23 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
SHUKRA PHARMACEUTICALS - TO CONSIDER ISSUANCE OF FULLY PAID UP BONUS EQUITY SHARES
Source text for Eikon: ID:nBSE2D4f3D
Further company coverage: SHUR.BO
(([email protected];;))
Feb 23 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
SHUKRA PHARMACEUTICALS - TO CONSIDER ISSUANCE OF FULLY PAID UP BONUS EQUITY SHARES
Source text for Eikon: ID:nBSE2D4f3D
Further company coverage: SHUR.BO
(([email protected];;))
Events:
Split
Dividend
Bonus
Dividend
Rights
Dividend
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Shukra Pharma do?
Relish Pharmaceuticals Limited is a global pharmaceutical company located in Ahmedabad, Gujarat. They manufacture, export, and market drugs and dosage forms for prestigious companies worldwide, aiming to exceed customer expectations in domestic and international markets.
Who are the competitors of Shukra Pharma?
Shukra Pharma major competitors are Fermenta Biotech, Anuh Pharma, Kwality Pharma, Wanbury, Kopran, Sudarshan Pharma Ind, Shree Ganesh Remed.. Market Cap of Shukra Pharma is ₹850 Crs. While the median market cap of its peers are ₹868 Crs.
Is Shukra Pharma financially stable compared to its competitors?
Shukra Pharma seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Shukra Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Shukra Pharma latest dividend payout ratio is 5.9% and 3yr average dividend payout ratio is 6.92%
How has Shukra Pharma allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Short Term Loans & Advances
How strong is Shukra Pharma balance sheet?
Balance sheet of Shukra Pharma is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Shukra Pharma improving?
The profit is oscillating. The profit of Shukra Pharma is ₹8.18 Crs for TTM, ₹18.54 Crs for Mar 2024 and ₹4.41 Crs for Mar 2023.
Is the debt of Shukra Pharma increasing or decreasing?
Yes, The debt of Shukra Pharma is increasing. Latest debt of Shukra Pharma is -₹15.31 Crs as of Sep-24. This is greater than Mar-24 when it was -₹16.64 Crs.
Is Shukra Pharma stock expensive?
Yes, Shukra Pharma is expensive. Latest PE of Shukra Pharma is 103, while 3 year average PE is 67.54. Also latest EV/EBITDA of Shukra Pharma is 84.78 while 3yr average is 24.26.
Has the share price of Shukra Pharma grown faster than its competition?
Shukra Pharma has given better returns compared to its competitors. Shukra Pharma has grown at ~220.66% over the last 2yrs while peers have grown at a median rate of 55.32%
Is the promoter bullish about Shukra Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Shukra Pharma is 50.96% and last quarter promoter holding is 50.96%.
Are mutual funds buying/selling Shukra Pharma?
There is Insufficient data to gauge this.